latest update:
[TrialBase DB]

trial summary · NCT07649161

Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism

The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics

Trial record from the TrialBase DB dataset, status RECRUITING, condition Healthy Adult, sponsored by Massachusetts General Hospital. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07649161phase —enrollment 50start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this clinical trial is to learn how nicotinamide riboside (NR), a form of vitamin B3, affects brain energy metabolism in healthy adults. Researchers want to find out if taking NR by mouth for 2 weeks can raise the balance of two related brain chemicals called NAD+ and NADH, which play a key role in how cells make and use energy. The main questions are: Does short term NR treatment increase the NAD+ to NADH ratio in the brain, and does it change other brain energy measures that we can see with a special type of MRI scan called phosphorus 31 MR spectroscopy. Adults between 18 and 65 years old who are generally healthy and do not have a personal or close family history of mood or psychotic disorders may be able to take part. People who join the study will first have a screening visit with a psychiatric interview and safety checks to confirm they are eligible and to review the risks and procedures. Eligible participants will then have a baseline visit that includes a blood draw, vital signs, urine drug and pregnancy tests when needed, and a 7 Tesla MRI/MRS scan focused on brain chemistry and structure. After the baseline visit, participants will take NR capsules by mouth at home, 1500 milligrams in the morning and 1500 milligrams in the early afternoon each day, for about 2 weeks, for a total daily dose of 3000 milligrams. They will be asked to avoid alcohol and other drugs during the study and to complete a short food diary near the end of the dosing period so that researchers can track diet. On the last day of taking NR, participants will return for repeat …

Source record: https://clinicaltrials.gov/study/NCT07649161

Facts

registry idNCT07649161
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionHealthy Adult
sponsorMassachusetts General Hospital
sponsor classOTHER
enrollment50
start date2026-12
primary completion2027-09
completion2028-01
results postednot reported

Conditions

  • Healthy Adult

Interventions

  • Niagen®

Countries

  • United States

Intervention types: DIETARY_SUPPLEMENT

Work with this record